Resources & Support

References

First Author
Nguyen, V V
Title
A human kidney and liver organoid-based multi-organ-on-a-chip model to study the therapeutic effects and biodistribution of mesenchymal stromal cell-derived extracellular vesicles.
Citation
Journal of extracellular vesicles; 2022 Nov; 11(11) pge12280
PubMed Id
36382606
Show Usages
Product Cited
Cross-Reactivity
Applications
AF-100-15
Human
in vitro
100-26
Human
in vitro
120-10C
Human
in vitro
100-39
Human
in vitro
120-03P
Human
in vitro
100-32
Human
in vitro
First Author
Mesci, P
Title
SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir.
Citation
PLoS biology; 2022 Nov; 20(11) pge3001845
PubMed Id
36327326
Show Usages
Product Cited
Cross-Reactivity
Applications
AF-100-15
Human
in vitro
450-02
Human
in vitro
450-03
Human
in vitro
450-10
Human
in vitro
First Author
Liu, W
Title
hUC-MSCs Attenuate Acute Graft-Versus-Host Disease through Chi3l1 Repression of Th17 Differentiation.
Citation
Stem cells international; 2022; 2022 pg1052166
PubMed Id
36277038
Show Usages
Product Cited
Cross-Reactivity
Applications
AF-300-02
Human
in vitro
AF-300-01A
Human
in vitro
AF-100-21C
Mouse
in vitro
216-16
Mouse
in vitro
211-11B
Mouse
in vitro
First Author
Tanaka, J
Title
Human induced pluripotent stem cell-derived salivary gland organoids model SARS-CoV-2 infection and replication.
Citation
Nature cell biology; 2022 Nov; 24(11) pg1595-1605
PubMed Id
36253535
Show Usages
Product Cited
Cross-Reactivity
Applications
100-19
Human
in vitro
100-26
Human
in vitro
First Author
Amri, N
Title
Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy.
Citation
Cells; 2022 Oct 4; 11(19)
PubMed Id
36231083
Show Usages
Product Cited
Cross-Reactivity
Applications
AF-200-06
Human
in vitro
300-02
Human
in vitro
First Author
Ma, Y
Title
Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19.
Citation
International immunopharmacology; 2022 Nov; 112 pg109283
PubMed Id
36201943
Show Usages
Product Cited
Cross-Reactivity
Applications
200-02
Human
in vitro
First Author
George, S
Title
Protocol to drive human monocyte-to-macrophage polarization in vitro using tumor conditioned media.
Citation
STAR protocols; 2022 Sep 19; 3(4) pg101666
PubMed Id
36125932
Show Usages
Product Cited
Cross-Reactivity
Applications
200-04
Human
in vitro
200-10
Human
in vitro
300-02
Human
in vitro
300-25
Human
in vitro
First Author
Karagiannis, F
Title
Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19.
Citation
Nature; 2022 Sep; 609(7928) pg801-807
PubMed Id
35901960
Show Usages
Product Cited
Cross-Reactivity
Applications
200-02
Human
in vitro
200-12
Human
in vitro
210-12
Mouse
in vitro
First Author
Kitajima, K
Title
An Interferon-γ/FLT3 Axis Positively Regulates Hematopoietic Progenitor Cell Expansion from Human Pluripotent Stem Cells.
Citation
Stem cells (Dayton, Ohio); 2022 Oct 21; 40(10) pg906-918
PubMed Id
35901509
Show Usages
Product Cited
Cross-Reactivity
Applications
120-05
Human
in vitro
100-20
Human
in vitro
First Author
Blasiak, A
Title
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens.
Citation
NPJ digital medicine; 2022 Jun 30; 5(1) pg83
PubMed Id
35773329
Show Usages
Product Cited
Cross-Reactivity
Applications
AF-100-15
Human
in vitro
showing 10 of 19161
Show More